Published 2017-07-01
How to Cite
Abstract
The aim of this study was to evaluate the efficacy of using appropriate biomarkers of inflammation for diagnosis of tuberculosis in children, monitoring the disease and the effects of the applied therapy.
Material and methods: In this study, 60 patients were included and divided into two groups: control group of 40 healthy children and a group of 20 children with tuberculosis. The subjects from both groups were aged from 1 to 15 years, matched by age. The children with tuberculosis were hospitalized for diagnostic and therapeutic treatment. None of them received corticosteroid therapy before treatment. Blood samples from patients with tuberculosis were taken just before the therapy and after 2 months. The concentration of three biomarkers close-related with the evolution of the disease was analyzed in blood sera: tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP) and procalcitonin (PCT). Serum concentrations of TNF-a were measured in vitro using IMMULITE 1000 analyzer for quantitative measurement of TNF-α in serum (EIA). Determination of CRP and PCT in serum was done with the quantitative method (ELFA) using i-CHROMA - immune analyzer.
Results: A statistically significant difference was found in the concentrations of TNFa serum before and after treatment (18.54 ± 1.94 v.s. 10.02± 0.640 pg/ml, p<0.05), СRP before and after therapy (99.59 ± 9.23 v.s 9.13 ± 1.13 mg/L, p<0.05), and РСТ (0.31 ± 0.02 v.s. 0.04 ± 0,01 ng/ml, p<0.05).
Conclusion: The results showed that tested biomarkers of inflammation are important for early diagnosis and monitoring the effects of the anti-tuberculosis therapy.Downloads
References
- World Health Organization. Global Tuberculosis Control:
- Surveillance, Planning, Financing. Geneva: World
- Health Organization; 2002.
- Casarini M, Aneglio F, Alemanno L. Cytokine levels correlate
- with a Radiologic Score in Active Pulmonary Tuberculosis.
- Am J Respir Crit Care Med. 1999; 159: 143-148.
- American Thoracic Society. Diagnostic Standard and
- Classification of Tuberculosis in Adult and Children.
- Am Respir Crit Care Med. 2000; 161:1376-1395.
- Andersen P, Munk ME, Doherty TM, еt al. Specific immune-
- based diagnosis of tuberculosis. Lancet. 2000;
- :1099-104.
- Alatas F, Alatas O, Metintas M. The rule of IL-12, IL-
- , TNFa, IFN- gama and TGF- betaA1 in pulmonary
- tuberculosis. Turkish Thoracic Society. 2002; 3
- (Suppl. 1):20-23
- Toossi Z. The inflammatory response in Mycobacterium
- tuberculosis infection. Arch Immunol Ther Exp.
- ; 48(6): 513-9.
- Gerbeaux J. Tuberculose primaire de L enfant. Rev Tuberc.
- ; 35:315.
- WHO. Global tuberculosis control:Survillance, Planning,
- Financing. Genova : World Health Organization;
- Roach DR, Briscoe H. Tumor necrosis factor (TNF)
- and a TNF-mimetic peptide modulate the granulomatous
- response to Mycobacterium bovis BCG infection
- in vivo. Infect Immun. 1999; 67(10): 5473-6.
- Che L, Lu J. Meаsurement of serum tumor necrosis
- factor-alfa and interleukin-8 in children with low respiratory
- tract infection (LRTI) caused by Mycoplazma
- pneumonia. ECACI. 1999; (1): 50-2.
- Comstock G. The International Tuberculosis Campaign:
- a pioneering venture in mass vaccination and research.
- Clin Infect Dis. 1994. 19 (3): 528–540.
- Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-
- based approach to diagnose pulmonary tuberculosis
- in children. Pediatrics. 2006; 118:1350-9.
- Marais BJ, Pai M. Recent advances in the diagnosis of
- childhood tuberculosis. Arch Dis Child. 2007; 92: 446-52.
- Kapotis C, Samara E. Determination of IL-4, IL-6, IL-8
- interleukins and TNF a in patients with tuberculosis
- during treatment. DMBS. 2003; (Suppl 2) : 22-23 .
- Knoring VE, Simbertsev AS. Changes in the production
- of interleukin-1beta, tumor necrosis factor- alfa
- and interleukin-2 in relation to the immunity
- in patients with pulmonary tuberculosis. Probl Tuberk.
- ; 4: 31-5.
- Beutler B, Krochin N. Control of cachectin/tumor necrosis
- factor. Science. 1986; 232: 977- 80.
- Schlag G, Redl H. Mediators of Injury and inflammation.
- World J Surg. 1996; 20: 406- 410
- Schiffman G. Tuberculosis Symptoms. Medicine Health;
- Gerbeaux J, Hanoteau J. Medications recentes dans le
- traiment de la tuberculose primaire. Rev Tuberc.
- ; 35:315
- Lebel H.M, Bishara J. Dexamethasone therapy for bacterial
- meningitis. N Engl J Med. 1988; 319: 964-71.
- Lambert H. The Chemioprophylaxis of Tuberculosis.
- Amer Rev Resp Dis. 1959; 80:648
- Keane J, Gershon S, Wise RP. Tuberculosis associated
- with infliximab, a tumor necrosis factor alfa-neutralizing
- agent. N Engl J Med. 2001; 345(15):1098-104.
- Mitrevski A. Using protein as a marker for inflammation
- and sepsis. Mac.Med.Review. 2005; 12: 25-26.
- National Institute for Health and Clinical Excellence.
- Tuberculosis: Clinical Diagnosis and Management of
- Tuberculosis and Measures for Its Prevention and
- Control.Clinical guideline 117. 2011.
- Barnes FP, Fong SJ, Brennan JP. Local production
- of tumor necrosis factor and IFN-g in tuberculous
- pleuritis. The Journal of Immunology. 1990;145:
- - 154.
- Casarini M, Aneglio F, Alemanno L. Cytokine levels
- correlate with a radiologic score in active pulmonary
- tuberculosis. Am J Respir Crit Care Med. 1999; 159:
- -148
- Pivet A, Chedevergne FM. Cytokine transcripts in pediatric
- tuberculosis: a study with bronchoalveolar
- cells. Tuber Lung Dis. 2000; 80(6): 249-58.
- Sester M et al. Interferon-� release assays for the diagnosis
- of active tuberculosis: a systematic review and
- meta-analysis. The European Respiratory Journal.
- ; 37: 100–11.
- Johnston W, Saltzman H, Bufkin J, Smith D. The Tuberculin
- Test and the Diagnosis of Clinical Tuberculosis.
- Amer Rev Resp Dis. 1960; 81: 189.
- Wilson CB, Lewis DB. Basis and implications of selectively
- diminished cytokine production in neonatal
- susceptibility to infection. Rev Infect Dis.
- ;12: 410-20.
- Al-Nawas B. Krammer I. Shah PM. Procalcitonin in
- diagnosis of severe infections. Bur J Med Res. 1996;
- (7): 331-3.
- Atanasova V. Rosmanova R. Andreeva H. Procalcitonin:
- an inovative marker for bacterial infections.Biochemical,
- immunologieal and clinical aspects. Clin
- AppI Immunol Invest. 2001; 1: 153-60.
- Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011; 378:
- –72.
- Ahmed N, Hasnain S. Molecular epidemiology of tuberculosis
- in India: Moving forward with a systems
- biology approach. Tuberculosis. 2011; 91: 407–413.
- Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis
- in children. Lancet Infect Dis. 2003; 3: 624-31.
- Vol.7 No.1 2015